Diversity of Potentially Pathogenic Escherichia coli O104 and O9 Serogroups Isolated before 2011 from Fecal Samples from Children from Different Geographic Regions

Armando Navarro 1*, Claudia van der Ploeg 2, Ariel Rogé 2, Delia Licona-Moreno 1, Gabriela Delgado 3, Rosario Morales-Espinosa 3, Alejandro Cravioto 4 and Carlos Eslava 5*

Abstract: In 2011, an outbreak of hemorrhagic colitis and hemolytic uremic syndrome (HUS) was reported in Europe that was related to a hybrid STEAEC of Escherichia coli (E. coli) O104:H4 strain. The current study aimed to analyze strains of E. coli O104 and O9 isolated before 2011. The study included 47 strains isolated from children with and without diarrhea between 1986 and 2009 from different geographic regions, as well as seven reference strains. Serotyping was carried out on 188 different geographic regions, as well as seven reference strains. Serotyping was carried out on 188

Keywords: Escherichia coli O104:H4; serotypes; virulence genes; STEAEC; DEC pathotypes

1. Introduction

In 2011, an outbreak of hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS) was reported in various European countries [1]. Those affected were adults over the age of 20 years and importantly, women were affected in greater numbers than men [2]. According to a preliminary report, more than four thousand cases and fifty deaths were registered [3]. While searching for the agent responsible for the outbreak, a strain of Escherichia coli (E. coli) STEC no-O157 of the O104:H4 serotype was identified. Genetic analysis of this strain showed the presence of the aatA, aggR, aap, agg, and aggC genes of enteroaggregative E. coli (EAEC) and stx2 of Shiga toxin-producing E. coli (STEC), leading to the notion that this was an STEAECA hybrid strain [4–6]. The term EAHEC was also proposed for strains that contain these genes, and they were identified as being
LEE-negative [7]. The emergence of this hybrid bacteria suggests an uncommon genetic recombination event, although some time before the reported outbreak in Germany in 2011, the participation of EAEC in HUS cases, including some O104 serogroup strains, had been reported [8,9]. The aforementioned outbreak reached other countries, such as Austria, Denmark, Germany, Holland, Norway, Spain, Sweden, Switzerland and England. In addition, cases were reported in individuals who had previously traveled to the region in Germany in which the outbreak originated [10]. The global report by the European Food Safety Authority reported that 16 European countries had been affected, as well as the United States of America [11]. Cases were also reported in individuals in Canada and the United States who had visited Germany some days before becoming sick [10]. The source of the outbreak caused by *E. coli* O104:H4 initially implicated cabbages, tomatoes, vegetable salad and cucumbers consumed raw. In fact, epidemiological evidence suggested that contaminated fenugreek seeds were the source of the outbreak [12–14].

One of the methods for characterizing *E. coli* strains is serological typing proposed by Kaufmann in the 1940s [15]. For a long time, this method was considered to be the gold standard to determine the antigenic characteristics of bacteria. Serological typing has been the standard tool for taxonomic and epidemiologic studies to characterize *E. coli* isolates during epidemic outbreaks associated with this bacterium. Serologic typing also allows new serogroup clusters to be established using DNA sequencing methodologies gene groups synthesized by the O antigen (O-antigen gene cluster (O-AGC)), or complete genome sequencing to develop genotypic methods to determine O antigen groups [16–18].

In our own laboratory, we carried out systematic *E. coli* typing using sera from rabbits prepared against 188 somatic antigens (O) and 56 flagella (H) according to the method reported by Ørskov [19]. While carrying out these studies, we identified antigenic reactivity shared between the O104 and O9 serogroup strains, suggesting that both serogroups could belong to the same clone. Given the epidemiologic importance that the O104 serogroup acquired, we carried out a review of our database in order to determine the isolation frequency of the *E. coli* O104 and O9 obtained from different epidemiologic studies carried out in our laboratory [20]. The results from this review showed that we housed isolates from Mexico, Egypt, Bangladesh and Argentina, although in Mexico there were no reports referring to HUS or HC related to *E. coli* O104. However, the existence of this microorganism in countries in which HUS and HC is not a public health problem suggests that the genotypic and phenotypic characteristics of the bacteria are unknown. It is for this reason that the current study looked at the antigenic cross-reaction between *E. coli* O104 and O9, the presence of diarrheagenic *E. coli* (DEC) gene groups that are associated with the pathogenesis of diarrhea in HUS and HC, and the potential clonal association of O104 and O9 strains in order to identify its epidemiologic impact, as observed in the 2011 outbreak in some European Union countries.

2. Materials and Methods
2.1. *E. coli* Strains

Of the 54 *E. coli* strains analyzed, 47 were fecal samples from 35 children under five years of age (30 with diarrhea and 5 without symptoms) obtained from epidemiologic studies carried out in Mexico [20], Egypt, Argentina and Bangladesh (obtained from International Centre for Diarrhoeal Disease Research, Bangladesh, ICDDR,B). In addition to these strains, four *E. coli* reference strains were included in the analysis (ECOR16, ECOR26, ECOR27, ECOR28), which were provided by Dr. Robert Selander in 1985 [21] (20), two *E. coli* O104:H4 strains obtained from the Statens Serum Institut (SSI) in 2013 and 2018 [22,23], and one O9:H12 (Bi3 16-42) strain from the Gastrointestinal Bacteria Reference Unit (GBRU), Public Health England, London, UK.
2.2. Serological Typing
In order to confirm the serotypes of the selected *E. coli* strains, serological typing used 188 sera (SERUNAM, Mexico) prepared against the somatic (O) antigen and 53 against the flagellar (H) antigen according to the method reported previously by Ørskov [19].

2.3. Antigenic Reactivity Compared between *E. coli* O104 and O9
Absorption of anti-O104 and O9 antibodies with corresponding antigens (O104 and O9) was carried out in the laboratory using the method described by Ewing [24] with minor modifications [25]. Using the absorbed sera, the antigenic relationship of *E. coli* O104 (H519) and O9 (Bi316-42) strains was analyzed by microagglutination test [19]. For this, the dilution at which each sera agglutinated was determined.

2.4. Detection of Virulence Genes
Using PCR and specific primers (Table 1), the presence of *eae*, *stx1*, *stx2*, *hlyA*, *aggR*, *aapA*, *aatA*, *aaiC*, *sat* and *fimH* genes present in the STEC, EAEC and UPEC pathotypes of *E. coli* were identified.

| Genes   | Nucleotide Sequence 5′-3′ | Product Size (pb) | Reference |
|---------|--------------------------|-------------------|-----------|
| *eae universal* | F: CCC GAA TTC GGC ACA AGC ATA AGC R: CCC GGA TCC GTC TCG CCA GTA TTC | 863 | [26] |
| *Stx1* | F: GTA CGG GGA TGC AGA TAA ATC GC R: AGC AGT CAT TAC ATA AGA ACG YCC ACT | 209 | |
| *Stx2* | F: GGC ACT GTC TGA AAC TGC TCC TGT R: AAT AAA CTG CAC TTC AGC AAA TCC | 625 | [27] |
|          | F4-f: CGC TGT CTG AGG CAT CTC CGC T R1e/f: TAA ACT TCA CCT GGG CAA AGC C | 627 | |
| *hlyA* | F: GGT GCA GCA GAA AAA GTT GTA G R: TCT CGC CTG ATA GTG TTT GGT A | 1551 | [28] |
| *aggR* | F: CTA ATT GTA CAA TCG ATG TA R: ATG AAG TAA TAC TTT AGG AAG | 308 | [29] |
| *aapA* | F: CTT TTC TGG CAT CTT GGG T R: GTA AC AAC CCC TTT GGA AGT | 232 | |
| *aatA* | F: ATG TTA CCA GAT ATA AAT ATA G R: CAT TCC CCC TGT ATT GGA AAT G | 1064 | [30] |
| *aaiC* | F: ATT GTG CTC CTC AGG CAT TCC ACA CG R: ACA CCC CTG ATA AAC AA | 215 | [31] |
| *sat* | F: GGTGAGTCCGGTGATGGGC R: CAAGCTCCGCTCGCTTGCCA | 412 | [32] |
| *fim H* | F: TGCAGAACGGGATAGACGCCGGTCGGTCA R: GCCAGTCCGGCCGGCGCTGGCA | 508 | [33] |
| *arpA* | F: AAC GCT ATT CGC CAG CTT GC R:TCT CCC CAT ACC GTA CGC TA | 400 | |
| *chuA* | F: ATG GTA CCG GAC GAA CCA AC R: TGC CGC CAG TAC CAA AGA CA | 288 | [34] |
| *yjaA* | F: CAA ACG TGA AGT GTC AGG AG R: AAT GCG TTC CTC AAC CTG TG | 211 | |
| *TspE4.C2* | F: CAC TAT TCG TAA GGT CAT CC R: AGT TTA TCG CTG CGG GTC GC | 152 | |
2.5. Phylogenetic Group

Phylogenetic groups (A, B1, B2, C, D, E, F and *Escherichia* cryptic clade I) of *E. coli* O104 y O9 were determined using PCR with primers for *arpA*, *chuA*, *yjaA* and *TspE4.C2* (Table 1) and previously reported conditions [34].

2.6. Antimicrobial Sensitivity

Sensitivity tests used the procedures and recommendations proposed in the Clinical & Laboratory Standards Institute (CLSI) 2017 manual [35]. Bacteria were grown on a nutrient agar plate and incubated at 37 °C for 24 h. A suspension of the resulting bacterial growth with a saline solution was prepared and adjusted to a 0.5 nephelometric McFarland tube (1.5 × 10^8 bacteria/mL). The suspension was inoculated into 2 Mueller-Hinton agar plates. Disks (BBL Sensi Disc BD®, Franklin Lakes, NJ, USA) with the following antimicrobials were placed on the surface of the inoculated agar plates at a distance of 24 mm between each: Cephalosporins 2nd generation: cefoxitin (FOX) 30 µg; 3rd generation: ceftriaxone (CRO) 30 µg, ceftazidime (CAZ) 30 µg, cefotaxime (CTX) 30 µg; 4th generation: cefepime (FEP) 30 µg; quinolones: ofloxacin (OFX) 5 µg, norfloxacin (NOR) 10 µg, nalidixic acid (NA) 30 µg, ciprofloxacin (CIP) 5 µg, imipenem (IPM) 10 µg, aztreonam (ATM) 30 µg, trimethoprim/sulfamethoxazole (SXT) 1.25/23.75 µg, tetracycline (TE) 30 µg. The plates were incubated at 37 °C for 16–18 h, and then the inhibition halos were measured to determine strain behavior. The tests used 25922 and 35218 reference strains from the American Type Culture Collection (ATCC).

2.7. Chromosomal Profiles by Pulse Field Gel Electrophoresis (PFGE)

Genomic DNA in agarose blocks was prepared using the method previously described in PulseNet (https://www.cdc.gov/pulsenet/participants/international/index.html (accessed on 18 September 2021)) with some modifications that included allowing bacterial growth for no more than 12 h, deproteinizing the DNA-plugs of the bacterial colony twice and increasing the number of washes (up to 8) of the DNA-plugs with TBE buffer. The XbaI (Sigma-Aldrich, St. Louis, MO, USA) enzyme was used to obtain chromosomal profiles. XbaI fragments were separated by a CHEF-Mapper device (Bio-Rad, Hercules, CA, USA). *Salmonella* Braenderup H9812 DNA restricted by XbaI was used as a molecular size marker. The gels were run at 12 °C, 6 V/cm and with a 120° switch angle for 19 h with a pulse time that ramped up from 2.16 s to 54.17 s. Following resolution and staining with ethidium bromide, each profile was viewed on a 1.0% agarose gel (Seakem Gold agarose, Lonza Rockland, Rockland, ME, USA).

The images were digitized by the Gel Logic 112 imaging system (Kodak, Rochester, NY, USA). The fingerprinting profile in the PFGE gel was analyzed using BioNumerics v.7.1 (AppliedMaths, Sint-Martens-Latem, Belgium) software package. After background subtraction and gel normalization, typing of fingerprint profiles was carried out, which was based on banding similarity and dissimilarity, using the Dice similarity coefficient and the Unweighted Pair Group Method with Arithmetic Mean (UPGMA) [36] according to average linkage clustering methods.

3. Results

3.1. Origin of the Strains

Of the 54 analyzed *E. coli* strains, 47 were obtained from clinical isolates, of which 5 (10.6%) were from Egypt, 4 (8.5%) from Argentina, 3 (6.4%) from Bangladesh and 35 (74.5 %) from Mexico.

3.2. Antigenic Elements Shared between *E. coli* O104 and O9

In order to ascertain that the agglutination assays with anti-O9 and anti-O104 sera were identifying the specific serogroup, absorption tests of both antisera using the heterologous antigen were carried out. The reactivity of anti-*E. coli* O9 serum against O9 and O104 antigens showed responses at dilutions of 1:1600 and 1:400, respectively. The same assay
for the anti-\textit{E. coli} O104 serum against O9 and O104 antigens showed a response at a dilution of 1:200 and 1:1600, respectively (Supplementary Table S1). The reactivity of the anti-O9 serum absorbed with the O104 antigen showed that reaction against this antigen was removed. Regarding the reactivity of the anti-O104 serum absorbed with the O9 antigen, reaction against the O104 antigen was eliminated. Following these results, absorbed antisera were used for each serogroup. The strains from the O104 serogroup showed agglutination response with its specific serum (anti-\textit{E. coli} O104 serum), a dilution of 1:400 without presenting any response against the specific anti-\textit{E. coli} O9 serum. Interestingly, the O9 serogroup strains reacted only to the specific anti-\textit{E. coli} O9 serum.

### 3.3. Serotypes, Phylogenetic Groups, Virulence Gene Content and Pathotypes of \textit{E. coli} O104 Strains

Serologic tests of the 47 clinically isolated strains showed that 13 corresponded to the O104 serogroup with the following serotypes: O104:H4 (38%), O104:H7 (8%) and O104:H21 (54%). The phylogenetic tests showed the strains belonged to phylogroups of commensal strains A (69%) and B1 (31%). PCR was used to identify virulence-associated genes (Table 2) detected a-EPEC/EAEC (7.7%), STEC (61.5%) and combinations of STEC/EAEC (30.8%) in the strains.

### 3.4. Serotypes, Phylogenetic Groups and Pathotypes of \textit{E. coli} O9 Strains

From a total of 34 strains belonging to serogroup O9, the following distribution of serotypes was found: O9:NM (nonmotile) (35.3%), O9:H4 (11.8%), O9:H9 (8.8%), O9:H10 (2.9%), O9:H11 (5.9%), O9:H21 (2.9%), O9:H25 (20.6%) and O9:H33 (11.8%). The majority (91%) of these belonged to the phylogroups defined as commensal A (62%) and B1 (29%), and with less frequency to the extraintestinal pathogenic B2 (3%) and C (6%). The main virulence genes detected were EAEC (34%), STEC (35%), STEC/EAEC (32%) and a-EPEC (6%), with no amplification being found in 3% of strains (Table 3).

### 3.5. Serotypes, Phylogenetic Groups and Genes Associated with Virulence in Reference Strains

Of the serotypes identified in the reference strains, two were O104:H4, one O104:H2 and two O104:H21, which belong to the phylogenetic groups A, D and B1. In these strains, the following genes were present: one \texttt{stx1}/\texttt{hlyA} (STEC), three with EAEC genes, one \texttt{eae}/\texttt{hlyA} (a-EPEC) and two not determined (ND) (Table 4). The O9 serogroup reference strains corresponded to O9:H12 from the GBRU collection within phylogenetic group A with \texttt{aggR} of EAEC. The other strain from the ECOR16 collection was serotype O9:H10 from phylogroup A that amplified \texttt{finH} (Table 4).

### 3.6. Sensitivity to Antimicrobials

Results from the sensitivity tests to various antimicrobials for the O104 and SSI strains showed that three (30%) were resistant to only one microbial (TE, SXT or NA), four (40%) to NA/TE and one (10%) to ATM/CAZ/NA (Table 5).

Results for the O9 strains showed resistance in 21 (62%) of the strains and of these, 13 were resistant to just one antimicrobial (SXT 3 (9%), TE 9 (27%) and ATM 1 (3%)) and eight were resistant to two antimicrobials (NA/TE 2 (6%) and TE/SXT 6 (18%)) (Table 6). The ECOR16, ECOR26, ECOR28 and O9:H12 (Bi3 16-42) strains were sensitive to all antimicrobials.
Table 2. Phylogenetic groups and virulence factors in *E. coli* O104 strains.

| Location | Year of Isolation | Origin | E. coli Serotypes | * Phylogenetic Group | Strains | Virulence Genes | Pathotype |
|----------|------------------|--------|------------------|---------------------|---------|-----------------|-----------|
| Mexico   | 1998             | ** IMSS | O104:H4          | B1                  |         | eae             |           |
|          |                  |        |                  |                     | 1       | 1, stx1, stx2   | a-EPEC/EAEC |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
|          | 2003             | ** IMSS | O104:H7          |                     |         |                 |           |
|          |                  |        |                  |                     | 1       | 1, stx1, stx2   | STEC      |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
|          | 2003             | ** IMSS | O104:H12         |                     | 1       | 1, stx1, stx2   | STEC      |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
| Egypt    | 1996             | Egypt  | O104:H4          | A                   | 1       | 1, stx1, stx2   | STEC/EAEC |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
| Argentina| 2003             | Argentina | O104:H12    | A                   | 1       | 1, stx1, stx2   | STEC      |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
| Bangladesh | 2009          | ** ICDDR,B | O104:H4    | A                   | 3       | 1, stx1, stx2   | STEC/EAEC |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |
|          | 2009             | ** ICDDR,B | O104:H12    | A                   | 1       | 1, stx1, stx2   | STEC/EAEC |
|          |                  |        |                  |                     | hlyA    | aggR            |           |
|          |                  |        |                  |                     | app     | aatA            |           |
|          |                  |        |                  |                     | aaiC    | sat             |           |
|          |                  |        |                  |                     | fimH    |                 |           |

| N (%)  | 13             | 12 (92) | 10 (77) | 4 (31) | 5 (39) | 5 (39) | 6 (46) | 5 (39) | 5 (39) | 5 (39) | 8 (62) |

* Group A: *arpA*+, chuA-, yjaA-, TspE4.C2-; group B1, *arpA*+, chuA-, yjaA-, TspE4.C2C+; group B2: *arpA*-, chuA+, yjaA+, TspE4.C2C+; group C: *arpA*+, chuA-, yjaA+, TspE4.C2C-. ** IMSS: Instituto Mexicano del Seguro Social (Mexican Institute of Social Security). *** International Centre for Diarrhoeal Disease Research, Bangladesh.
Table 3. Diversity of diarrheagenic groups in E. coli O9 strains.

| Location | Isolation Year | Origin | Serotype | Phylogenetic Group * | Strains | Virulence Genes | Pathotype |
|----------|----------------|--------|----------|----------------------|---------|-----------------|-----------|
|          |                |        |          |                      |         | eae             |           |
|          |                |        |          |                      |         | stx1            |           |
|          |                |        |          |                      |         | hlyA            |           |
|          |                |        |          |                      |         | aggR            |           |
|          |                |        |          |                      |         | app             |           |
|          |                |        |          |                      |         | aaiA            |           |
|          |                |        |          |                      |         | sat             |           |
|          |                |        |          |                      |         | fimH            |           |
|          |                |        |          |                      |         | STEC            |           |
|          |                |        |          |                      |         | EAEC            |           |
|          |                |        |          |                      |         | STEC/EAEC       |           |
|          |                |        |          |                      |         | a-EPEC          |           |
| Mexico   | 1986           | Tlaltizapan 1, Mor. | O9:NM   | A                    | 5       | -               | -         |
|          | 1986           |        | O9:NM   | A                    | 1       | -               | -         |
|          | 1986           |        | O9:H9   | A                    | 2       | -               | -         |
|          | 1986           |        | O9:H10  | A                    | 1       | -               | -         |
|          | 1987           |        | O9:H11  | B1                   | 2       | -               | -         |
|          | 1986           |        | O9:NM   | C                    | 2       | -               | -         |
| Mexico   | 1996           | ** IMSS | O9:H4   | A                    | 1       | -               | -         |
|          | 1996           |        | O9:H33  | A                    | 2       | -               | -         |
|          | 1996           |        | O9:H4   | A                    | 3       | -               | -         |
|          | 1996           |        | O9:H33  | A                    | 2       | -               | -         |
|          | 1996           |        | O9:NM   | C                    | 1       | -               | -         |
|          | 2000           |        | O9:H21  | B1                   | 1       | -               | -         |
|          | 2000           |        | O9:H25  | B1                   | 3       | -               | -         |
|          | 2000           |        | O9:H25  | B1                   | 4       | -               | -         |
| Egypt    | 1997           | Egypt  | O9:NM   | B2                   | 1       | -               | -         |
|          | 1997           |        | O9:NM   | A                    | 1       | -               | -         |
|          | 1999           |        | O9:NM   | A                    | 1       | -               | -         |
|          | 1999           |        | O9:H9   | A                    | 1       | -               | -         |

N (%) 34 4 (12) 23 (68) 6 (18) 19 (56) 8 (24) 3 (9) 6 (18) 33 (97)

1 Cravioto A, [20]. * Group A: arpA+, chuA-, yjaA-, TspE4.C2-; Group B1, arpA+, chuA-, yjaA-, TspE4.C2C2-; group B2: arpA-, chuA+, yjaA+, TspE4.C2C2+; group C: arpA+, chuA-, yjaA+, TspE4.C2C-. All O9 strains were negative for stx2 and aaiC. ** IMSS: Instituto Mexicano del Seguro Social (Mexican Institute of Social Security).
| Origin     | Year of Isolation | E. coli Serotypes | Phylogenetic Group | Strains | Virulence Genes | Pathotype |
|------------|-------------------|-------------------|--------------------|---------|-----------------|-----------|
| ECOR26     | 1984              | O104:H21          | A                  | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | a-EPEC    |
| ECOR27     |                   | O104:H21          |                    | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | STEC      |
| ECOR28     |                   | O104:H2            |                    | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | ND        |
| SSI        | 2013              | O104:H4           | D                  | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | EAEC      |
|            | 2018              | O104:H4           | B1                 | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | EAEC      |
| GBRU       | 1999              | O9:H12            | A                  | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | EAEC      |
| ECOR16     | 1984              | O9:H10            |                    | 1       | 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 | 1         | ND        |
| N (%)      |                   |                   |                    | 7       | 1 (14), 1 (14), 3 (43), 3 (43), 2 (29), 2 (29), 2 (29), 2 (29), 5 (71) |           |           |

All the reference strains did not present the stx2. ECOR: Escherichia coli reference. SSI: Statens Serum Institute. GBRU: Gastrointestinal Bacteria Reference Unit, Public Health England, London, UK. ND: Not determined.
Table 5. Resistance patterns of *E. coli* O104 strains.

| Country | Year of Isolation | Serotype | Strains | Number of Strains Antimicrobial Resistance |
|---------|------------------|----------|---------|------------------------------------------|
| Mexico  | 1998             | O104:H4  | 1       | ATM 1 CAZ R NA TE SXT 1 |
|         | 2003             | O104:H12 | 2       | ATM 1 CAZ R NA TE 2 |
|         |                   | O104:H12 | 1       | ATM 1 CAZ R NA TE 3 |
| Egypt   | 1996             | O104:H4  | 1       | ATM 1 |
| Bangladesh | 2009          | O104:H4  | 1       | ATM 1 |
|         |                   | O104:H4  | 2       | ATM 2 |
| SSI     | 2013–2018        | O104:H4  | 2       | ATM 2 |

N (%) 10 1 (10) 1 (10) 7 (70) 7 (70) 3 (30)

ATM: Aztreonam. CAZ: Ceftazidime. SXT: Trimethoprim/sulfamethoxazole. NA: Nalidixic Acid. TE: Tetracycline.

Table 6. Resistance patterns of *E. coli* O9 strains.

| Country | Year of Isolation | Origin    | Serotype | Strains | Antimicrobial Resistance | Total Antimicrobials |
|---------|------------------|-----------|----------|---------|--------------------------|-----------------------|
| Mexico  | 1986–1987        | Taltizapan Mor., 1 | O9:NM    | 2       | ATM R 1 |
|         |                   |           | O9:NM    | 1       | ATM R 1 |
|         |                   |           | O9:NM    | 2       | ATM R 2 |
|         |                   |           | O9:H10   | 1       | ATM R 1 |
|         |                   |           | O9:H11   | 2       | ATM R 2 |
| Mexico  | 1996             | ** IMSS   | O9:NM    | 1       | ATM R 1 |
|         |                   |           | O9:H33   | 2       | ATM R 2 |
|         |                   |           | O9:H4    | 1       | ATM R 1 |
|         |                   |           | O9:H33   | 1       | ATM R 2 |
|         |                   |           | O9:H-     | 1       | ATM R 1 |
| Egypt   | 1999             | ** IMSS   | O9:H25   | 2       | ATM R 1 |
|         |                   |           | O9:H25   | 1       | ATM R 1 |
|         |                   |           | O9:H25   | 2       | ATM R 2 |
|         |                   |           | O9:NM    | 1       | ATM R 1 |
|         |                   |           | O9:NM    | 1       | ATM R 2 |

Total N (%) 21 (62) 1 (3) 1 (3) 11 (32) 6 (18)

1 Cravioto A, [20]. ** IMSS: Instituto Mexicano del Seguro Social (Mexican Institute of Social Security). ATM: Aztreonam. NA: Nalidixic Acid. TE: Tetracycline. SXT: Trimethoprim/sulfamethoxazole.

3.7. Pulsed-Field Gel Electrophoresis (PFGE)

Using PFGE (Figure 1), 49 electrophoretic types were seen that formed two main branches (I and II). In branch I, the largest number of strains grouped together to form three clusters (A, B and C). Of these, cluster A was made up of five subgroups. In the first subgroup, two O104:H4 strains isolated in 2013 and 2018 from the SSI were located, and both strains were positive for *aggR* (EAEC) and *sat*, which are both genes present on the DEC strains of the EAEC pathogens. In this subgroup, an O104:H4 strain isolated in
Bangladesh (2009) also presented eae/aggR/stx1/sat genes, and the similarity between this strain and the two from the SSI was 93.3%. Two strains isolated in Mexico were also present in this first subgroup. One of the Mexican strains was O9:H4 and presented aggR/stx1/fimH, while the other, which was an O9:NM strain isolated in 1986, presented stx1 and was fimH-positive. The similarity between these five strains was 89.7%.

Two O9:H4 strains isolated in Mexico and positive for aggR/stx1/fimH, and one O9:NM strain isolated in Egypt in 1999 harboring aggR/fimH, belonged to the second subgroup. An O104:H21 (ECOR27) strain isolated in 1984 was also located in this subgroup and presented stx1/fimH. The similarity between these strains was 88.2%.

The third subgroup comprised four O104:H4 strains: one strain from Argentina isolated in 2003, two strains from Bangladesh isolated in 1996 and 2009, and one strain from Mexico isolated in 1998. The similarity between these four strains was 82.6%. The strain from Argentina harbored eae/stx1/sat/fimH, the strains from Egypt and Bangladesh were positive for eae/aggR/stx1/sat and the isolate from Mexico presented eae/aggR/fimH.

In the fourth subgroup, serotypes O9:H21 from Mexico isolated in 1996 and O9:NM from Egypt isolated in 1987 harbored aggR and fimH genes. A strain of O9:H12 (sc399) that presented aggR and fimH also belonged to this subgroup. The similarity between members of the fourth subgroup was 86.3%.

Five strains belonged to subgroup five. Three were serotype O9:NM, two of which were isolated in Mexico in 1986 and 1987, while the third was isolated in Egypt in 1999. The fourth strain was an O104:H7 strain isolated in Mexico in 2003 and presented eae/stx1/fimH genes, and the final strain was O104:H2 (ECOR28) that had no virulence genes (ND). The similarity between these five strains was 80.1%.

Cluster B comprised three subgroups. In the first subgroup, there were three strains of O104:H12 isolated in Mexico in 2003 that were positive for eae/stx1/stx2/fimH, one O104:H4 strain from Bangladesh isolated in 2009 that presented aggR/eae/stx1, and one O104:H21 (ECOR26) strain that harbored eae/fimH. The second subgroup was made up of three O104:H12 strains isolated in Argentina in 2003, all of which were positive for eae, stx1/stx2/fimH. The third subgroup was formed by an O104:H12 strain isolated in Argentina in 2003 that presented eae/stx1/stx2/fimH, and three strains isolated in Mexico, O9:H10 and O9:NM both isolated in 1986, and O9:H33 isolated in 1996, which harbored aggR/stx1/fimH, aggR/fimH and eae/stx1/sat/fimH, respectively. The similarity between these strains was 89.2%.

Eight strains isolated in Mexico in 1986, 1987 and 1996 grouped into cluster C with the following serotypes: O9:NM, O9:H4, O9:H9, O9:H10, O9:H11 and O9:H33. Of these, four presented stx1/fimH: two aggR/stx1/fimH, one sat/fimH and one eae/sat/fimH. One strain belonged to an isolated group, namely O9:H10 (ECOR16), with no virulence genes (ND) and a similarity of 71.7% in branch I.

Branch II contained two clusters identified as X and Y. In the latter Y cluster, there were ten strains from Mexico isolated in 1986, 1999 and 2000 with serotypes O9:NM, O9:H11 and O9:H25. Of these, four were positive for aggR/stx1/fimH, another four for aggR/fimH, one presented stx1/sat/fimH, and the final strain presented stx1/stx2/fimH. Similarity between strains of the Y cluster was between 80.6% and 100%. Cluster X showed lower similarity (69.8%) with branches I and II and included two O9:H33 strains from Mexico isolated in 1996, one which was positive for eae/sat/fimH and the other for eae/stx1/sat/fimH, and an O9:NM from Egypt isolated in 1999, which presented aggR/stx1/sat/fimH. The similarity between the two Mexican strains was 91.7% and between those and the strain from Egypt was 78.4%.
4. Discussion

STEC and EAEC are important pathogens; the former causes HUS and the latter persistent diarrhea. In 2011, a new hybrid variant emerged in European countries that was a strain of the *E. coli* O104:H4 serotype that presented genes of both the STEC and EAEC pathotypes [1]. This current study provides data for *E. coli* strains of serotype O9 and O104 isolated in different regions and at different times before the HUS outbreak in Europe in 2011 that was caused by *E. coli* O104:H4. We isolated *E. coli* strains from children under five years of age with and without diarrhea, whose fecal samples were characterized by presenting the *stx1*-*stx2* genes in combination with EAEC genes.

Antigenic cross-reactions between O9 and O104 antigens. Analysis of the absorption tests for anti-*E. coli* O9 and anti-*E. coli* O104 showed that antigenic cross-reactions were
eliminated. Results also revealed the presence of common epitopes between both antigens. Previous studies have reported that the LPS of *E. coli* O104 presents a structural similarity to the K9 capsular antigens of *E. coli* O9 [19,37,38]. Bearing this in mind, the antigenic reactions in the *E. coli* O9 and O104 strains of this study could be due to common epitopes between these two LPSs. Such antigenic cross-reactions have been reported in human serum and cow’s milk [39,40]. This is relevant because it provides a starting point to look for common epitopes between the different antigens in order to develop protective vaccines against these pathogens.

Serotypes and virulence genes, phylogenetic groups and diarrheagenic groups of *E. coli* O104 strains. Serotyping analysis showed the presence of three serotypes for *E. coli* O104 (H4, H7 and H12), with O104:H4 being the most frequent. These strains were isolated in Mexico, Egypt and Bangladesh before 2011. An interesting characteristic of these strains was that they presented virulence factors similar to the European O104:H4 strains and were identified as STEC, STEC/EAEC and aEPEC/EAEC hybrids. One microbiological property of the *E. coli* O104:H4 strains isolated during the outbreak in 2011 is that they presented stx2 and aggR genes. However, *E. coli* O104 strains of the present study harbored STEC genes in different combinations. In the Egyptian and Bangladeshi strains, eae was detected in combination with stx1, aggR, aap and aatA. This last characteristic corresponds with the *E. coli* O104:H4 strains (aggR, aap and aatA) from Germany [4]. The presence of the eae gene in our study strains is not only a difference from the O104:H4 strains from the outbreak in Germany but also from other O104 strains isolated from cow’s milk and various sources for which the absence of the eae gene has been reported [41,42]. The two O104:H4 strains obtained from the SSI were found in the EAEC group based on the presence of aggR, aatA and aaiC genes and the absence of stx1 and stx2 genes. The diarrheagenic groups identified in the SSI strains correspond to O104 strains from Mexico, Egypt and Bangladesh in that they contained the EAEC genes (aggR, aatA and aaiC). However, there was a difference since our study strains presented the eae gene, which led them to be grouped as STEC/EAEC and a-EPEC/EAEC. The lack of the stx1 and stx2 genes in the O104:H4 strains from the SSI was an important difference with respect to the 2011 epidemic outbreak in Europe. However, the genes in the SSI strains corresponded to that reported in the fourth and eighth External Quality Assessment (4th EQA and 8th EQA) carried out by the SSI in 2013 and 2018 [22,23].

Another interesting serotype identified in our study was *E. coli* O104:H7. This serotype presented the eae gene and for this reason, it was classified as atypical EPEC (a-EPEC), which is a difference from other strains with the same serotype isolated from cases of human diarrhea and sheep that were reported as being positive for stx and negative for eae [41–43]. With this in mind, it has been proposed that cattle and sheep could be possible reservoirs for O104:H7 [41,43]. Another serotype identified in our study was O104:H12 from Mexico, Argentina and Bangladesh, which was classified as STEC, and STEC/EAEC. This serotype has been reported as being present in rectal swabs of cattle, but without the stx gene [40,41]. In contrast, in our study strains, the stx1 and eae genes were detected indicating the diverse genotypes that can be found in O104 strains.

Serologic typing of the ECOR26, ECOR27 and ECOR28 strains identified two serotypes, namely O104:H21 and O104:H2. These results are in line with those reported by Amor and Johnson [44,45] and initially reported by T Whittam in the Thomas Whittam Laboratory website (http://www.bio.psu.edu/People/Faculty/Whittam/Lab/ecor/ (accessed on 18 September 2021) [45]). This shows that the typing of *E. coli* using 188 anti-O sera continues to be valid for providing knowledge of antigenic characteristics of different strain collections and origins.

A similar situation to that of the *E. coli* O104 serotypes was observed in *E. coli* O9 serotypes in that the serotypes isolated in Mexico according to gene presence were classified as STEC, and STEC/EAEC pathotypes. These characteristics correspond to STEC strains isolated from healthy pigs and O9:NM strains from human infection [46–48]. However, these strains classified as STEC differ from O9 strains isolated from dairy cattle from
different parts of Mexico in that the stx1 genes were not identified, although they did share the genes of the EAEC pathotype [40].

Some bacterial structures, such as adhesins and more specifically FimH, have been related to adherence to human epithelial cells, which allows the persistence of bacteria in the intestine. We explored our study strains for the presence of the specific adhesin mannose (fimH) of E. coli. Interestingly, serogroup O104 as well as serogroup O9 presented the fimH gene, which confers with the study reported by Shridhar [41] in which strains of the O104:H7 serotype isolated from both humans and cattle presented the fimH gene. However, the role of this gene is controversial, given that it has been found as much in virulent strains as in commensal strains [49,50], but there is no doubt that it does play a role in the initial colonization of the human intestine, and as with adhesin, it favors epithelial cell adherence of the intestine and urinary tract.

Phylogenetic groups. The serotypes of the O9 and O104 serogroups of this study belong mainly to phylogroups A and B1, which are classified as commensal bacteria, and they form the normal microbiota of human, pig and bovine intestine [51,52]. Due to these E. coli strains carrying STEC and EAEC genes, they could be considered as hybrid strains, as was the case of E. coli O104:H4 isolated from the 2011 epidemic in Germany [53]. However, the O104:H4 strains isolated in Mexico, Bangladesh and a percentage isolated by the SSI were located in phylogenetic group B1, a characteristic that corresponds to strains in the German HUS outbreak, as well as to strains from other studies in which they were located in the same B1 phylogroup [54–56]. However, while O104 strains were located in groups considered to be commensal according to the Clermont system [34], other authors report that the presence of virulence factors may not correlate with phylogenetic groups of E. coli [57]. It is for this reason that the presence of E. coli strains with virulence factors in commensal phylogroups is a frequent occurrence. The O9 serogroup strains were located in phylogroups A, B1, B2 and C with the exception of one O9:NM strain that was located in phylogroup B2, while the majority of serotypes were located in commensal groups. This was similar to the O104 strains given that they showed the presence of the stx1, aggR and fimH genes, and to a lesser extent eae and sat, which were determined as EAEC and STEC/EAEC. Miko and Delannoy [38,42] reported that O9 serotype strains presented the K9 capsular antigen but lacked the stx gene. However, in a previous study [40], strains with different serotypes of the E. coli O9 serogroup were located in commensal groups A and B1 and presented the eae and aggR genes. The aggR gene was present in strains from our study, and previous reports suggest that the strains of serotype O9 isolated from humans and animals were STEC no-O157 [48]. In the case of strains from humans, they were related to HUS [58].

Results for O104 showed antimicrobial resistance mainly to NA, TE and SXT, while O9 showed resistance to SXT and TE. This pattern of resistance was similar to that reported for E. coli O157 strains isolated from different sources, and STEC no-O157 strains isolated from dairy cattle [40,59]. However, this pattern of resistance for O104 strains was different to that reported for E. coli O104:H4 strains from the German outbreak. These strains were characterized by producing extended spectrum b-lactamase (CTX-M-15) and being resistant to ampicillin, third generation cephalosporins, nalidixic acid, SXT and TE, but sensitive to fluoroquinolones [5,12]. With respect to the O9 strains, they presented differences from isolated O9 strains from dairy cattle raised in Mexico [40]. The latter were characterized as being multi-resistant to antimicrobials, which is different from the O9 strains in this study that presented resistance against SXT and TE only.

In general, electrophoretic analysis of the O104 and O9 strains showed them to be diverse and heterogeneous, and there was no grouping by origin, serotype or phylogenetic groups. However, it is important to note that the two O104:H4 strains from the SSI presented an electrophoretic profile similar to that of strains with genes from the EAEC group, locating them in the same subgroup as an O104:H4 strain isolated from Bangladesh in 2009 and two strains isolated in 1986 and 1996 in Mexico with an O9:H4 and O9:H- serotype, respectively. The similarity between the Bangladeshi and Mexican strains and
the O104:H4 strains from the SSI was 93.3% and 87.8%, respectively. This narrow location could indicate a clonal relationship between these strains, which would be interesting in order to determine if they could have a common origin.

Another interesting result was the location of the O9:H4 and O9:H- strains isolated in Mexico and Egypt, together with the ECOR27 (O104:H21) strain, which was isolated from a Giraffe in a zoo in Washington, United States [21,45]. In the referenced study, the serotype was reported as being O104:NM [45], but in our study using the serological typing system established in our laboratory, the serotype was identified as O104:H21, which corresponds with reports made by Johnson and Amor [44,45].

The ECOR28 (O104:H2) strain was isolated from a woman in Iowa, United States [21], and the serotyping results corresponded with other studies [44,45] reporting that no virulence genes were detected, similar to serotype O104:H2 isolated from human diarrhea lacking stx genes that was reported by Miko [41].

It is noteworthy that the ECOR26 strain with an O104:H21 serotype was isolated from a child in the United States, and a strain of O104:H4 isolated in Bangladesh in 2009 had a similarity of 93.0% despite being isolated in different geographical locations, years apart, and having distinct serotypes. However, clonally they are very close, which could indicate a wide geographical circulation of these strains.

5. Conclusions

Our study reports *E. coli* O104 and O9 strains isolated from different geographical locations and time periods, which present genes from various DEC groups indicating genetic plasticity and horizontal gene transfer. In addition, the results show the ability for recombination of these microorganisms in order to become incorporated into the genetic material of the genome of other DEC groups [60–62]. The study also reveals the importance of *E. coli* serotyping, which in conjunction with genotyping methods could be used in epidemiological surveillance of *E. coli* outbreaks given the wide distribution of strains with pathogenic potential.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/microorganisms9112227/s1, Table S1: Agglutination titers of anti-O9 and O104 sera without unabsorbed and absorbed.

Author Contributions: Conceptualization, A.N. and C.E.; investigation and methodology, C.v.d.P., A.R., D.L.-M., G.D. and R.M.-E., writing—review and editing, A.N., A.C. and C.E. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from Secretaría de Educación, Ciencia, Tecnología e Innovación de la Ciudad de México (SECTEI-CDMX) Project 9200c19.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to thank Gabriel Pérez, Luis Antonio León and José Luis Méndez (Faculty of Medicine, UNAM) for their technical assistance in the laboratory. We also like to thank Jesús Canales Bravo and Brenda Guadalupe Hernández Santiago, from FES Cuautitlán, UNAM and the Faculty of Chemistry, UNAM.

Conflicts of Interest: The authors declare that there are no competing interests associated with the manuscript.

References

1. Beutin, L.; Martin, A. Outbreak of Shiga Toxin–Producing Escherichia Coli (STEC) O104:H4 Infection in Germany Causes a Paradigm Shift with Regard to Human Pathogenicity of STEC Strains. *J. Food Prot.* 2012, 75, 408–418. [CrossRef] [PubMed]
2. Frank, C.; Faber, M.S.; Askar, M.; Bernard, H.; Fruth, A.; Gilsdorf, A.; Höhle, M.; Karch, H.; Krause, G.; Prager, R.; et al. Large and Ongoing Outbreak of Haemolytic Uraemic Syndrome, Germany, May 2011. *Eurosurveillance* 2011, 16. [CrossRef]
27. Scheutz, F.; Teel, L.D.; Beutin, L.; Piérard, D.; Buvens, G.; Karch, H.; Mellmann, A.; Caprioli, A.; Tozzoli, R.; Morabito, S. Multicenter Evaluation of a Sequence-Based Protocol for Subtyping Shiga Toxins and Standardizing Stx Nomenclature. *J. Clin. Microbiol.* 2012, 50, 2951–2963. [CrossRef]  

28. Schmidt, H.; Beutin, L.; Karch, H. Molecular Analysis of the Plasmid-Encoded Hemolysin of Escherichia Coli O157: H7 Strain EDL 933. *Infect. Immun.* 1995, 63, 1055–1061. [CrossRef] [PubMed]  

29. Huang, D.B.; Mohamed, J.A.; Nataro, J.P.; DuPont, H.L.; Jiang, Z.-D.; Okhuysen, P.C. Virulence Characteristics and the Molecular Epidemiology of Enteraggregative Escherichia Coli Isolates from Travellers to Developing Countries. *J. Med. Microbiol.* 2007, 56, 1386–1392. [CrossRef]  

30. Nishi, J.; Sheikh, J.; Mizuguchi, K.; Luisi, B.; Burland, V.; Beutin, A.; Rose, D.J.; Blattner, F.R.; Nataro, J.P. The Export of Coat Protein from Enteraggregative Escherichia Coli by a Specific ATP-Binding Cassette Transporter System. *J. Biol. Chem.* 2003, 278, 45680–45689. [CrossRef] [PubMed]  

31. Balabanova, Y.; Klar, S.; Delere, Y.; Wilking, H.; Faber, M.S.; Lassen, S.G.; Gilsdorf, A.; Dupke, S.; Nitschke, M.; Sayk, F. Serological Evidence of Asymptomatic Infections during Escherichia Coli O104: H4 Outbreak in Germany in 2011. *PLoS ONE* 2013, 8, e73052. [CrossRef] [PubMed]  

32. Morales-Espinosa, R.; Hernández-Castro, R.; Delgado, G.; Mendez, J.L.; Navarro, A.; Manjarrez, Á.; Cravioto, A. UPEC Strain Characterization Isolated from Mexican Patients with Recurrent Urinary Infections. *J. Infect. Dev. Ctries.* 2016, 10, 317–328. [CrossRef]  

33. Johnson, J.R.; Stell, A.L. Extended Virulence Genotypes of Escherichia Coli Strains from Patients with Urosepsis in Relation to Phylogeny and Host Compromise. *J. Infect. Dis.* 2000, 181, 261–272. [CrossRef]  

34. Clermont, O.; Christenson, J.K.; Denamur, E.; Gordon, D.M. The Scherichia Coli Phylo-typing Method Revisited: Improvement of Specificity and Detection of New Phylo-groups. *Environ. Microbiol. Rep.* 2013, 5, 58–65. [CrossRef] [PubMed]  

35. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*, 27th ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017.  

36. Day, W.H.; Edelsbrunner, H. Efficient Algorithms for Agglomerative Hierarchical Clustering Methods. *J. Classif.* 1984, 1, 7–24. [CrossRef]  

37. Kogan, G.; Jann, B.; Jann, K. Structure of the Escherichia Coli O104 Polysaccharide and Its Identity with the Capsular K9 Polysaccharide. *FEMS Microbiol. Lett.* 1992, 91, 135–140. [CrossRef]  

38. Delannoy, S.; Beutin, L.; Burgos, Y.; Fach, P. Specific Detection of Enteraggregative Hemorrhagic Escherichia Coli O104: H4 Strains by Use of the CRISPR Locus as a Target for a Diagnostic Real-Time PCR. *J. Clin. Microbiol.* 2012, 50, 3485–3492. [CrossRef]  

39. Balabanova, Y.; Klar, S.; Delere, Y.; Wilking, H.; Faber, M.S.; Lassen, S.G.; Gilsdorf, A.; Dupke, S.; Nitschke, M.; Sayk, F. Serological Evidence of Asymptomatic Infections during Escherichia Coli O104: H4 Outbreak in Germany in 2011. *PLoS ONE* 2013, 8, e73052. [CrossRef] [PubMed]  

40. Navarro, A.; Cauich-Sánchez, P.I.; Trejo, A.; Gutiérrez, A.; Díaz, S.P.; Díaz, C.M.; Cravioto, A.; Eslava, C. Characterization of Diarrheagenic Strains of Escherichia Coli Isolated from Cattle Raised in Three Regions of Mexico. *Front. Microbiol.* 2018, 9, 2373. [CrossRef]  

41. Shridhar, P.B.; Patel, I.K.; Gangiredla, J.; Noll, L.W.; Shi, X.; Bai, J.; Elkins, C.A.; Stockbne, N.A.; Nagaraja, T. Genetic Analysis of Virulence Potential of Escherichia Coli O104 Serotypes Isolated from Cattle Feces Using Whole Genome Sequencing. *Front. Microbiol.* 2018, 9, 341. [CrossRef] [PubMed]  

42. Miko, A.; Delannoy, S.; Fach, P.; Stockbne, N.A.; Lindstedt, B.A.; Mariani-Kurkdjian, P.; Reetz, J.; Beutin, L. Genotypes and Virulence Characteristics of Shiga Toxin-Producing Escherichia Coli O104 Strains from Different Origins and Sources. *Int. J. Med. Microbiol.* 2013, 303, 410–421. [CrossRef]  

43. Enríquez-Gómez, E.; Talavera-Rojas, M.; Soriano-Vargas, E.; Navarro-Ocaña, A.; Vega-Sánchez, V., de Oca, S.A.-M.; Acosta-Dibarrat, J. Serotypes, Virulence Genes Profiles and Antimicrobial Resistance Patterns of Escherichia Coli Recovered from Feces of Healthy Lambs in Mexico. *Small Rumin. Res.* 2017, 153, 41–47. [CrossRef]  

44. Amor, K.; Heinrichs, D.E.; Fridrich, E.; Ziebell, K.; Johnson, R.P.; Whitfield, C. Distribution of Core Oligosaccharide Types in Lipopolysaccharides from Escherichia Coli. *Infect. Immun.* 2000, 68, 1116–1124. [CrossRef]  

45. Johnson, J.R.; Delavari, P.; Kuskowski, M.; Stell, A.L. Phylogenetic Distribution of Extraintestinal Virulence-Associated Traits in Escherichia Coli. *J. Infect. Dis.* 2001, 183, 78–88. [CrossRef] [PubMed]  

46. Kaufmann, M.; Zweifel, C.; Blanco, M.; Blanco, J.; Blanco, J.; Beutin, L.; Stephan, R. Escherichia Coli O157 and Non-O157 Shiga Toxin-Producing Escherichia Coli in Fecal Samples of Finished Pigs at Slaughter in Switzerland. *J. Food Prot.* 2006, 69, 260–266. [CrossRef]  

47. DesROSiers, A.; Fairbrother, J.M.; Johnson, R.P.; Desautels, C.; Letellier, A.; Quessy, S. Phenotypic and Genotypic Characterization of Escherichia Coli Verotoxin-Producing Isolates from Humans and Pigs. *J. Food Prot.* 2001, 64, 1904–1911. [CrossRef]  

48. WHO/CSR/APH/98.8. World Health Organization Zoonotic Non-O157 Shiga Toxin-Producing *Escherichia coli* (STEC). In Proceedings of the WHO Scientific Working Group Meeting, Berlin, Germany, 23–26 June 1999; World Health Organ: Geneva, Switzerland, 1999.  

49. Li, D.; Shen, M.; Xu, Y.; Liu, C.; Wang, W.; Wu, J.; Luo, X.; Jia, X.; Ma, Y. Virulence Gene Profiles and Molecular Genetic Characteristics of Diarrheagenic Escherichia Coli from a Hospital in Western China. *Gut Pathog.* 2018, 10, 1–11. [CrossRef] [PubMed]
50. Klemm, P.; Schembri, M.; Hasty, D.L. The FimH Protein of Type 1 Fimbriae. Anti-Adhes. Ther. Microb. Dis. 1996, 408, 193–195.

51. Bok, E.; Mazurek, J.; Stosik, M.; Wojciech, M.; Baldy-Chudzik, K. Prevalence of Virulence Determinants and Antimicrobial Resistance among Commensal Escherichia Coli Derived from Dairy and Beef Cattle. Int. J. Environ. Res. Public. Health 2015, 12, 970–985. [CrossRef]

52. Tomazi, T.; Coura, F.; Gonçalves, J.; Heinemann, M.; Santos, M. Antimicrobial Susceptibility Patterns of Escherichia Coli Phylogenetic Groups Isolated from Bovine Clinical Mastitis. J. Dairy Sci. 2018, 101, 9406–9418. [CrossRef] [PubMed]

53. Baquero, F.; Tobes, R. Bloody Coli: A Gene Cocktail in Escherichia Coli O104: H4. MBio 2013, 4, e00066-13. [CrossRef]

54. Mora, A.; Herrrera, A.; López, C.; Dahbi, G.; Mamani, R.; Pita, J.M.; Alonso, M.P.; Llovo, J.; Bernárdez, M.I.; Blanco, J.E. Characteristics of the Shiga-Toxin-Producing Enteroaggregative Escherichia Coli O104: H4 German Outbreak Strain and of STEC Strains Isolated in Spain. Int Microbiol 2011, 14, 121–141.

55. Prager, R.; Lang, C.; Aurass, P.; Fruth, A.; Tietze, E.; Flieger, A. Two Novel EHEC/EAEC Hybrid Strains Isolated from Human Infections. PLoS ONE 2014, 9, e95379. [CrossRef] [PubMed]

56. Patel, I.R.; Gangiredla, J.; Lacher, D.W.; Mammel, M.K.; Jackson, S.A.; Lampel, K.A.; Elkins, C.A. FDA Escherichia Coli Identification (FDA-ECID) Microarray: A Pangenome Molecular Toolbox for Serotyping, Virulence Profiling, Molecular Epidemiology, and Phylogeny. Appl. Environ. Microbiol. 2016, 82, 3384–3394. [CrossRef] [PubMed]

57. Wurpel, D.J.; Beatson, S.A.; Totsika, M.; Petty, N.K.; Schembri, M.A. Chaperone-Usher Fimbriae of Escherichia coli. PLoS ONE 2013, 8, e52835. [CrossRef] [PubMed]

58. Thomas, A.; Cheasty, T.; Chart, H.; Rowe, B. Isolation of Vero Cytotoxin-Producing Escherichia Coli Serotypes O9ab:H- and O101:H-Carrying VT2 Variant Gene Sequences from a Patient with Haemolytic Uraemic Syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, 1074–1076. [CrossRef]

59. Schroeder, C.M.; Zhao, C.; DebRoy, C.; Torcolini, J.; Zhao, S.; White, D.G.; Wagner, D.D.; McDermott, P.F.; Walker, R.D.; Meng, J. Antimicrobial Resistance of Escherichia Coli O157 Isolated from Humans, Cattle, Swine, and Food. Appl. Environ. Microbiol. 2002, 68, 576–581. [CrossRef] [PubMed]

60. Gogarten, J.; Doolittle, W.F.; Lawrence, J.G. Prokaryotic evolution in light of gene transfer. Mol. Biol. Evol. 2002, 19, 2226–2238. [CrossRef]

61. Schubert, S.; Darlu, P.; Clermont, O.; Wieser, A.; Magistro, G.; Hoffmann, C.; Weinert, K.; Tenillon, O.; Matic, I.; Denamur, E. Role of Intraspecies Recombination in the Spread of Pathogenicity Islands within the Escherichia Coli Species. PLoS Pathog. 2009, 5, e1000257. [CrossRef]

62. Gyles, C.; Boerlin, P. Horizontally Transferred Genetic Elements and Their Role in Pathogenesis of Bacterial Disease. Vet. Pathol. 2014, 51, 328–340. [CrossRef] [PubMed]